Pharmagel ha diffuso questo post
2024: A Year of Resilience and Impact At Paediatis, we started 2024 with unwavering determination despite the setback of a failed funding round in January. But success isn’t only measured by fundraising—it's about creating tangible, lasting impact. Thanks to the trust of our historical investor, the bank, Bpifrance, the Région Nouvelle-Aquitaine, and above all, our clients and partners Groupe Hospitalier Littoral Atlantique, 1400 jours pour Bébé® La Rochelle Université, LILOK, Mayoly Pharmagel and so many others, we achieved key milestones: - Patent registration in France - Second design and model registered - Featured in various media (WEDEMAIN, La NA le Mag, Placéco, PHARMAnetwork…) - First submission to the ANSM Agence nationale de sécurité du médicament et des produits de santé - 2 co-developments launched - Collaboration with the EBI-IHES at the Université de Poitiers Antoine DUPUIS - Publication in the "Journal of Drug Delivery Science and Technology https://lnkd.in/egADtZCe - Partnership sealed with the leader in Softgel technology - Carbon footprint minimized (proven by a Life Cycle Assessment with APESA) Our takeaway from 2024: staying grounded and mission-focused drives long-term success. Thank you to everyone who believed in us. Wishing you the best for the 11 months coming ! Picture taken by : Thierry Martrou #Innovation #Paediatrics #PharmaceuticalIndustry #Sustainability #LifeCycleAssessment #Collaboration #Impact #StartUpSuccess #DrugDelivery #Resilience #Partnerships #HealthTech #CarbonFootprint #ANSM #Patents